Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches | Journal of Urology
Treatment & Management of Prostate Cancer - CancerConnect
Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions | American Society of Clinical Oncology Educational Book
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial - ScienceDirect
Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer? | MedPage Today
Novel Targets and Treatment Developments in Metastatic Hormone Sensitive Prostate Cancer
Chemotherapy and Beyond: The Changing Face of Systemic Therapy for Prostate Cancer
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial - The Lancet
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations | Prostate Cancer and Prostatic Diseases
Modern treatment of metastatic prostate cancer | Tidsskrift for Den norske legeforening
Chemotherapy for Prostate Cancer
FDA Approves Relugolix for Advanced Prostate Cancer - NCI
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data - The Lancet Oncology
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer - ScienceDirect
Docetaxel radiosensitizes castration-resistant prostate cancer by downregulating CAV-1: International Journal of Radiation Biology: Vol 0, No 0
Cancers | Free Full-Text | Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1–6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes
Diagnostics | Free Full-Text | Genome-Based Classification and Therapy of Prostate Cancer
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial - ScienceDirect
Clinical trials for docetaxel treatment in prostate cancer in EU... | Download Scientific Diagram
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - The Lancet Oncology
Drugs For Prostate Cancer Treatment | Onco.com
ADT as Treatment in Metastatic Prostate Cancer
Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer | NEJM
Advances in the treatment of metastatic prostate cancer: Trends in Cancer
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol - The
A Clinically-Achievable Injectable and Sprayable in Situ Lyotropic Liquid Crystalline Platform in Treating Hormone-Sensitive and Castration-Resistant Prostate Cancer | ACS Nano
